423 results on '"myelodysplastic syndrome"'
Search Results
2. Effects of PTPN6 Gene Knockdown in SKM-1 Cells on Apoptosis, Erythroid Differentiation and Inflammations
- Author
-
Li Yu, Xiaoli Gu, Pengjie Chen, Rui Yang, Yonggang Xu, and Xiupeng Yang
- Subjects
PTPN6 ,SKM-1 cells ,myelodysplastic syndrome ,apoptosis ,erythroid differentiation ,Biology (General) ,QH301-705.5 - Abstract
Objective: Protein tyrosine phosphatase non-receptor type 6 (PTPN6) is a cytoplasmic phosphatase that acts as a key regulatory protein in cell signaling to control inflammation and cell death. In order to investigate the role of PTPN6 in hematologic tumor myelodysplastic syndrome (MDS), this study infected SKM-1 cell line (MDS cell line) with packaged H_PTPN6-shRNA lentivirus to obtain H_PTPN6-shRNA SKM-1 stable strain. The effect of PTPN6 knockdown on apoptosis, erythroid differentiation, and inflammations in SKM-1 cell line was examined. Methods: The stable knockdown SKM-1 cell line was validated using qPCR and Western blot assays. The proliferation activity, apoptosi, erythroid differentiation, and inflammatory cytokines in SKM-1 cells were assessed before and after transfection. Results: qPCR confirmed that the expression level of H_PTPN6-shRNA in SKM-1 cells was significantly reduced, and Western blot showed that the protein expression level of H_PTPN6-shRNA in SKM-1 cells was also significantly reduced. The CCK-8 cell viability assay confirmed that stable gene knockdown did not affect cell viability. Flow cytometry revealed that the apoptosis rate of cells in the PTPN6 knockdown group was 0.8%, lower than the 2.7% observed in the empty plasmid group; the expression rate of the erythroid differentiation marker CD235a was 13.2%, lower than the 25.0% observed in the empty plasmid group. The expression levels of the proinflammatory factors IL-6 and IL-8 increased, and the expression levels of the inhibitor factor IL-4 decreased. Conclusions: The PTPN6 gene was successfully knocked down using lentivirus-mediated transduction, and the constructed cell line was validated using PCR and Western blot. The CCK-8 cell viability assay confirmed that stable gene knockdown did not affect cell proliferation viability. Flow cytometry analysis of apoptosis and erythroid differentiation indicated that PTPN6 knockdown inhibits apoptosis and erythroid differentiation in SKM-1 cells and also alters the level of inflammations in the bone marrow microenvironment. It suggests that the PTPN6 gene acts as a tumor suppressor in myelodysplastic syndrome cells, influencing hematopoietic cell apoptosis, erythroid differentiation, and inflammations. This provides a reliable experimental basis for further in-depth studies on the mechanism of PTPN6 in MDS and related pharmacological research.
- Published
- 2024
- Full Text
- View/download PDF
3. Trisomy 14 as the only cytogenetic abnormality in myelodysplastic syndrome
- Author
-
M. N. Pautova, L. E. Koloskova, O. I. Filippova, and A. V. Koloskov
- Subjects
myelodysplastic syndrome ,dysplasia ,cytogenetic abnormality ,trisomy chromosomes 14 ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Evaluation of bone marrow cytogenetic abnormalities in myelodysplastic syndrome is of great importance for confirming the clonal disease nature, determining the prognosis and choosing treatment tactics. Cytogenetic abnormalities are detected in 40–70 % of patients with myelodysplastic syndrome, and the variety of these abnormalities reflects the disease characteristics.This article describes the clinical follow-up of a patient with a myelodysplastic neoplasia with blast excess 1 and trisomy of chromosome 14.
- Published
- 2024
- Full Text
- View/download PDF
4. Landscape of biallelic DNMT3A mutant myeloid neoplasms
- Author
-
Naomi Kawashima, Yasuo Kubota, Carlos Bravo-Perez, Luca Guarnera, Nakisha D. Williams, Arda Durmaz, Michaela Witt, Arooj Ahmed, Carmelo Gurnari, Jaroslaw P. Maciejewski, and Valeria Visconte
- Subjects
DNMT3A mutation ,Acute myeloid leukemia ,Myelodysplastic syndrome ,Myeloproliferative neoplasms ,Diseases of the blood and blood-forming organs ,RC633-647.5 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract DNA methyltransferase 3 A mutations (DNMT3A MT) are frequent in myeloid neoplasia (MN) and mostly heterozygous. However, cases with multiple DNMT3A MT can be also encountered but their clinical and genetic landscape remains unexplored. We retrospectively analyzed 533 cases with DNMT3A MT identified out of 5,603 consecutive MNs, of whom 8.4% had multiple DNMT3A MT hits. They were most frequent in acute myeloid leukemia (AML) with R882 variant accounting for 13.3% of the multi-hits. Multiple DNMT3A MT more likely coincided with IDH2 (P = 0.005) and ETV6 (P = 0.044) mutations compared to patients with single DNMT3A MT. When the sum of variant allele frequencies (VAFs) for multiple DNMT3A MT exceeded 60%, we found a significant positive clonal burden correlation of the two DNMT3A variants (P
- Published
- 2024
- Full Text
- View/download PDF
5. Higher prevalence of poor prognostic markers at a younger age in adult patients with myelodysplastic syndrome – evaluation of a large cohort in India
- Author
-
Vivi M. Srivastava, Sukesh Chandran Nair, Melvin Joy, Marie-Therese Manipadam, Uday P. Kulkarni, Anup J. Devasia, N.A Fouzia, Anu Korula, Kavitha M. Lakshmi, L. Jeyaseelan, Aby Abraham, and Alok Srivastava
- Subjects
Myelodysplastic syndrome ,Chromosomal abnormality ,Clinical risk groups ,Complex karyotype ,Cytogenetics ,Cytogenetic prognosis groups ,Genetics ,QH426-470 - Abstract
Abstract Background The karyotype is a major determinant of prognosis in myelodysplastic syndrome (MDS). Details of the cytogenetic profile of MDS in South Asia are limited because cytogenetic services are not widely available. Methods We performed a retrospective analysis of the cytogenetic and clinicopathologic profile of adult primary MDS seen consecutively at a tertiary-care centre in South India between 2003 and 2017. Patients were re-categorised according to the 2022 World Health Organisation (WHO) and the International Consensus classifications (ICC). Results There were 936 patients aged 18–86 years (median age 53, 65% males), with MDS with del 5q, low blasts and increased blasts in 7.5%, 58.4% and 34.1% respectively. Clonal abnormalities were seen in 55% of patients, with solitary abnormalities in 29.8% and complex karyotypes (CK, ≥ 3 abnormalities) in 15%. The most frequent abnormalities were monosomy 7/deletion 7q (16.1%), deletion 5q (14.5%), trisomy 8 (11.5%), and deletion 20q (5.1%). Cytogenetic prognosis groups were distributed as follows: very good, 2%; good, 55.6%; intermediate, 16.2%; poor, 15%; very poor, 11.2%. Clinical (IPSS-R) risk stratification (842 patients) showed: very low-risk, 3.9%; low-risk, 30.9%; intermediate-risk, 24.2%; high-risk, 21%; very high-risk, 20%. Age-adjustment (IPSS-RA) raised the very low-risk group to 12.4%; the other groups decreased by 1–3% each. Conclusion The most significant finding of this cytogenetic analysis of MDS in India is that abnormal karyotypes with poor prognosis markers including monosomy 7 and CK were more frequent than in most other reports, among patients who were overall younger. Trisomy 8, deletion 20q, the IPSS-R intermediate-risk and both high-risk groups were more common than in the West. Trisomy 8 was less common than in South-East Asia while CK and deletion 20q were comparable. Evaluation of such large cohorts highlights the unique features of MDS in different parts of the world. These findings suggest that there could be differences in predisposing factors, environmental or genetic, and emphasise the need for further exploration to better understand the varied nature of MDS.
- Published
- 2024
- Full Text
- View/download PDF
6. Ultralow-dose irradiation enables engraftment and intravital tracking of disease initiating niches in clonal hematopoiesis
- Author
-
Kevin Lee, Wimeth Dissanayake, Melissa MacLiesh, Cih-Li Hong, Zi Yin, Yuko Kawano, Christina M. Kaszuba, Hiroki Kawano, Emily R. Quarato, Brian Marples, Michael Becker, Jeevisha Bajaj, Laura M. Calvi, and Shu-Chi A. Yeh
- Subjects
Clonal hematopoiesis ,Myelodysplastic syndrome ,Fluorescence imaging ,Time-lapse imaging ,Multiphoton microscopy ,Cancer microenvironment ,Medicine ,Science - Abstract
Abstract Recent advances in imaging suggested that spatial organization of hematopoietic cells in their bone marrow microenvironment (niche) regulates cell expansion, governing progression, and leukemic transformation of hematological clonal disorders. However, our ability to interrogate the niche in pre-malignant conditions has been limited, as standard murine models of these diseases rely largely on transplantation of the mutant clones into conditioned mice where the marrow microenvironment is compromised. Here, we leveraged live-animal microscopy and ultralow dose whole body or focal irradiation to capture single cells and early expansion of benign/pre-malignant clones in the functionally preserved microenvironment. 0.5 Gy whole body irradiation (WBI) allowed steady engraftment of cells beyond 30 weeks compared to non-conditioned controls. In-vivo tracking and functional analyses of the microenvironment showed no change in vessel integrity, cell viability, and HSC-supportive functions of the stromal cells, suggesting minimal inflammation after the radiation insult. The approach enabled in vivo imaging of Tet2 +/− and its healthy counterpart, showing preferential localization within a shared microenvironment while forming discrete micro-niches. Notably, stationary association with the niche only occurred in a subset of cells and would not be identified without live imaging. This strategy may be broadly applied to study clonal disorders in a spatial context.
- Published
- 2024
- Full Text
- View/download PDF
7. Computing cell state discriminates the aberrant hematopoiesis and activated microenvironment in Myelodysplastic syndrome (MDS) through a single cell genomic study
- Author
-
Xinyu Guo, Wenyan Jin, Yuchen Wen, Zhiqin Wang, Xiaotong Ren, Zhaoyun Liu, Rong Fu, Zhigang Cai, and Lijuan Li
- Subjects
Myelodysplastic syndrome ,Single cell omics ,Computational hematopoiesis ,Bone marrow cell reference ,HMGA1 ,Medicine - Abstract
Abstract Background Myelodysplastic syndrome (MDS) is a complicated hematopoietic malignancy characterized by bone marrow (BM) dysplasia with symptoms like anemia, neutropenia, or thrombocytopenia. MDS exhibits considerable heterogeneity in prognosis, with approximately 30% of patients progressing to acute myeloid leukemia (AML). Single cell RNA-sequencing (scRNA-seq) is a new and powerful technique to profile disease landscapes. However, the current available scRNA-seq datasets for MDS are only focused on CD34+ hematopoietic progenitor cells. We argue that using entire BM cell for MDS studies probably will be more informative for understanding the pathophysiology of MDS. Methods Five MDS patients and four healthy donors were enrolled in the study. Unsorted cells from BM aspiration were collected for scRNA-seq analysis to profile overall alteration in hematopoiesis. Results Standard scRNA-seq analysis of unsorted BM cells successfully profiles deficient hematopoiesis in all five MDS patients, with three classified as high-risk and two as low-risk. While no significant increase in mutation burden was observed, high-risk MDS patients exhibited T-cell activation and abnormal myelogenesis at the stages between hematopoietic stem and progenitor cells (HSPC) and granulocyte–macrophage progenitors (GMP). Transcriptional factor analysis on the aberrant myelogenesis suggests that the epigenetic regulator chromatin structural protein-encoding gene HMGA1 is highly activated in the high-risk MDS group and moderately activated in the low-risk MDS group. Perturbation of HMGA1 by CellOracle simulated deficient hematopoiesis in mouse Lineage-negative (Lin-) BM cells. Projecting MDS and AML cells on a BM cell reference by our newly developed MarcoPolo pipeline intuitively visualizes a connection for myeloid leukemia development and abnormalities of hematopoietic hierarchy, indicating that it is technically feasible to integrate all diseased bone marrow cells on a common reference map even when the size of the cohort reaches to 1,000 patients or more. Conclusion Through scRNA-seq analysis on unsorted cells from BM aspiration samples of MDS patients, this study systematically profiled the development abnormalities in hematopoiesis, heterogeneity of risk, and T-cell microenvironment at the single cell level.
- Published
- 2024
- Full Text
- View/download PDF
8. Low Levels of Natural Killer Cell in Newly Diagnosed Myelodysplastic Syndromes Patients May Confer Poor Prognosis: A Retrospective Cohort Study
- Author
-
Gong S and Shi C
- Subjects
myelodysplastic syndrome ,lymphocyte subsets ,prognostic ,ipss-r ,natural killer cell ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Shengping Gong,1 Cong Shi2 1Cancer Radiotherapy and Chemotherapy Center, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, People’s Republic of China; 2Laboratory of Stem Cell Transplantation, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, 315000, People’s Republic of ChinaCorrespondence: Cong Shi, Email shicong5103@sina.comBackground: Immune imbalance appears to have a critical role in tumor growth according to emerging research. Peripheral lymphocyte subsets are considered to reflect the systemic immune response and clinical prognosis. The prognostic value of lymphocyte subpopulations in myelodysplastic syndrome (MDS) patients remains unclear.Methods: A total of 94 MDS patients were enrolled for the study. X-tile software was performed to determine the prognostic significance of various lymphocyte subpopulations, CD3, CD4, CD8, CD4/CD8 ratio, natural killer cell (NK) and CD19. Among them, the appropriate threshold of NK percent could be found only. Patients were divided into the high NK percent group and the low NK percent group. The prognostic significance was determined by univariate and multivariate Cox hazard models.Results: MDS patients with lower NK level had significantly shorter overall survival (OS). Based on univariate analysis, male gender (P = 0.030), lower HB (< 10 g/dl, P = 0.029), higher BM blast (> 5%, P < 0.0001), higher-risk IPSS-R cytogenetic (P = 0.032) and lower NK percent (P < 0.0001) were significantly associated with shorter OS. Multivariate Cox proportional hazards regression analysis indicated that low NK was also independent adverse prognostic factor for OS in MDS.Conclusion: Decreased NK level predicts poor prognosis independent of the IPSS-R and provide a novel evaluation factor for MDS patients.Keywords: myelodysplastic syndrome, lymphocyte subsets, prognostic, IPSS-R, natural killer cell
- Published
- 2024
9. Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma
- Author
-
Kazuki Yanagida, Taketo Kawai, Toyoshi Seito, Kensuke Matsumoto, Tomoyuki Kaneko, and Tohru Nakagawa
- Subjects
eltrombopag ,enfortumab vedotin ,myelodysplastic syndrome ,urothelial carcinoma ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Introduction Enfortumab vedotin is an antibody‐drug conjugate targeting Nectin‐4 for the treatment of advanced urothelial carcinoma in patients previously treated with platinum‐containing chemotherapy and immune checkpoint inhibitors. Common adverse events include rashes, peripheral neuropathy, and hyperglycemia. However, there are no reports on the development of myelodysplastic syndrome during enfortumab vedotin therapy in clinical settings. Case presentation A 72‐year‐old male patient experienced prolonged and severe thrombocytopenia 18 weeks after the start of enfortumab vedotin therapy for metastatic urothelial carcinoma, requiring daily platelet transfusions. Bone marrow examination and chromosomal analysis confirmed the diagnosis of myelodysplastic syndrome. Treatment with eltrombopag proved to be effective. Conclusion This is the first report of the development of myelodysplastic syndrome during enfortumab vedotin therapy in a clinical setting. Although rare, myelodysplastic syndrome can occur during enfortumab vedotin therapy.
- Published
- 2024
- Full Text
- View/download PDF
10. Iron overload impact on peripheral blood cells, lymphocytes and karyotypes in newly diagnosed myelodysplastic syndromes (MDS) patients: a single-center retrospective analysis
- Author
-
Lixiang Duan, Wenjun Yu, Xiaolin Jiao, Ying Sun, Yao Fang Ma, Le Li, Zeqiang Nie, and Dan Zhao
- Subjects
iron overload ,myelodysplastic syndrome ,lymphocyte subsets ,peripheral blood cells ,karyotype ,Biotechnology ,TP248.13-248.65 ,Life ,QH501-531 - Abstract
We conducted a retrospective analysis of 68 newly diagnosed myelodysplastic syndrome (MDS) patients who were treated in the Department of Hematology at Yuncheng Central Hospital affiliated to Shanxi Medical University from October 2017 to March 2022. Based on the serum ferritin (SF) level, the newly diagnosed MDS patients were divided into two groups: iron overload (IOL) group (SF > 1000 ng/mL) and non-iron overload (NIOL) group(SF ≤ 1000 ng/mL). General clinical data, peripheral blood cells, lymphocyte subsets and marrow karyotypes were compared. We found that MDS patients with IOL had lower hemoglobin (Hb), lower reticulocyte (RET) counts, and lower absolute natural killer (NK) cell counts compared with NIOL group (p
- Published
- 2024
- Full Text
- View/download PDF
11. Variation characteristics and clinical significance of TP53 in patients with myeloid neoplasms
- Author
-
Qiang Ma, Yan Liu, Hong Zhao, Yixian Guo, Wanling Sun, and Ronghua Hu
- Subjects
Myelodysplastic syndrome ,acute myeloid leukemia ,TP53 mutation ,VAF ,variation characteristics ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Objectives: MDS and AML characterized by TP53 variations have a poor prognosis in general. However, specifically, differences in prognosis have also been observed in patients with different TP53 variants and VAFs.Methods: Here, we retrospectively analyzed datasets of patients with MDS, MPN, and AML who underwent targeted DNA sequencing from February 2018 to December 2023, and patients with reportable TP53 variations were screened. Demographic data and clinical data were collected, and the relationship between TP53 alterations and patient prognosis (AML/MDS) was analyzed using the cBioPortal and Kaplan–Meier Plotter databases. The relationship between the VAFs of TP53 variations and prognoses was analyzed using data from the present study.Results: Sixty-two variants of TP53 were identified in 58 patients. We mainly identified single mutations (79.31%, 46/58), followed by double (17.24%, 10/58) and triple (3.45%, 2/58) mutations. The variations were mainly enriched in exon4–exon8 of TP53. Missense (72.58%, 45/62) mutations were the main type of variations, followed by splice-site (9.68%, 6/62), nonsense (9.68%, 6/62), frameshift (6.45%, 4/62), and indel (1.61%, 1/62) mutations. In this study, p.Arg175His and p.Arg273His were high-frequency TP53 mutations, and DNMT3A and TET2 were commonly co-mutated genes in the three types of myeloid neoplasms; However, we reported some new TP53 variants in MPN that have not been found in the public database. Moreover, MDS or AML characterized by altered TP53 had a shorter OS than patients in the unaltered group (P
- Published
- 2024
- Full Text
- View/download PDF
12. Down-regulation of A20 mRNA expression in peripheral blood mononuclear cells from MDS patients
- Author
-
Kai Wang, Tianyu Si, Congmin Wei, Qi Hu, Yongming Zhou, and Jizhang Bao
- Subjects
Myelodysplastic syndrome ,A20 ,mRNA ,peripheral blood mononuclear cells ,inflammatory signaling ,IL-8 ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
ABSTRACTMyelodysplastic syndrome (MDS) is characterized by activated inflammatory signaling and affects prognosis. Targeting inflammatory signaling may provide a way to treat the disease. We were curious whether there were changes in A20 in peripheral blood mononuclear cells (PBMC) of MDS patients. Therefore, we conducted a study with 60 clinical samples, including 30 MDS patients and 30 healthy controls. All patients with MDS were diagnosed and classified according to the criteria of the 2016 World Health Organization. The study was performed in accordance with the guidelines of the Declaration of Helsinki. Using Quantitative Real-Time RT–PCR, we discovered that A20 mRNA expression in PBMC of the MDS group was significantly lower than that in the control group (P
- Published
- 2024
- Full Text
- View/download PDF
13. Case report: VEXAS syndrome and literature review
- Author
-
Can Jones, Stanislav Ivanov, Pablo Ferraro, Souhad Younes, and Hugo Fernandez
- Subjects
VEXAS ,myelodysplastic syndrome ,UBA1 mutation ,inflammation ,bone marrow transplant ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
VEXAS syndrome (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) is a novel disorder first described in 2020. Patients are diagnosed by identifying a somatic mutation of the ubiquitin-like modifier-activating enzyme 1 (UBA1) gene. They usually have systemic inflammation and present with a combination of hematologic and rheumatologic abnormalities such as myelodysplastic syndrome and polychondritis. VEXAS syndrome patients are at increased risk of developing hematologic malignancies. We present a case of a 60-year-old male who developed transfusion-dependent macrocytic anemia, was found to have UBA1 mutation in the bone marrow, and was diagnosed with VEXAS syndrome. The patient responded well to steroid treatment and did not require more blood transfusion. The two main goals of treating VEXAS syndrome are eradicating the UBA1 mutated hematopoietic cells and inhibiting the inflammatory process. Early stem cell transplant evaluation is necessary as VEXAS-related complications may limit the efficacy of transplantation. Further research is required to improve the prognosis and quality of life of VEXAS syndrome patients.
- Published
- 2024
- Full Text
- View/download PDF
14. COVID-19 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): a propensity matched analysis (2020-2021)
- Author
-
Barath Prashanth Sivasubramanian, Shashvat Joshi, Diviya Bharathi Ravikumar, Madhumithaa Jagannathan, Sonia Babu, Shanthi Reddy Sripathi, Avinash Javvaji, Priyanshu Jain, Dinesh Kumar Shanmugam, Bharath Duraisamy Swami Kannan, Raghavendra Tirupathi, and Rutul Dalal
- Subjects
AML ,myelodysplastic syndrome ,COVID-19 ,severe sepsis ,ARDS ,acute respiratory failure ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundBy 2023, COVID-19 had caused 6.8 million deaths in the United States. COVID-19 presents more severely in leukemia compared to solid tumors (OR 1.6, p
- Published
- 2024
- Full Text
- View/download PDF
15. The consensus on the diagnosis and treatment of elderly myelodysplastic neoplasm in China (2024)
- Author
-
MDS Professional Committee of Hematology Branch of Chinese Geriatrics Society
- Subjects
geriatrics ,myelodysplastic syndrome ,myelodysplastic neoplasm ,diagnosis ,treatment ,Medicine - Abstract
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid tumours originating from haematopoietic stem/progenitor cells, with a high prevalence in the elderly. Epidemiological surveys in Europe and the United States have revealed that the incidence of MDS is (4-5)/100 000, which increases with age,and the median age at diagnosis of MDS patients reaches 73-76 years. In Shanghai, China, according to the World Health Organization (WHO) 2008 diagnostic criteria, the average incidence rate was 1.51/100 000, and the median age of onset of MDS was found to be 62 years old in a survey conducted in 3.9 million people from 2004 to 2007, of which about one-third of the patients would be transformed into acute myeloid leukemia (AML), and 53% of the patients would die due to infections, haemorrhages, or comorbidities triggered by cytopenias. Elderly MDS patients have their own characteristics in terms of both treatment choices and disease prognosis due to more comorbidities and weaker health. Clinical characteristics of elderly MDS patients include slightly higher white blood cell count, haemoglobin level and more bone marrow blasts than those of young patients, while neutrophil count and platelet count are significantly higher than those of young patients; the number of mutations in elderly MDS patients is higher, with an average of 1.8 mutations per patient, among which the mutations in ASXL1, TET2, SF3B1, STAG2, SRSF2 and TP53 are more common; while the number of mutations in younger patients averages 1.2 per person, among which U2AF1, ASXL1 and RUNX1 mutations are more common. Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for MDS, and myeloablative transplantation is feasible in young patients, but only reduced-intensity conditioning (RIC) allo-HSCT can be performed in elderly patients.The natural course and prognosis of elderly MDS patients varies considerably, and the MDS Composite Prognostic Score, which is composed of the composite age (>70 years old), vulnerability index, and IPSS prognostic subgroups, is able to better predict the tolerance of chemotherapy and adverse treatment effects in MDS patients. This consensus is based on the latest evidence-based data in the study of MDS in the elderly at home and abroad, and has been discussed by the experts of the group, which aims to standardise the diagnosis and the whole management of treatment for elderly MDS patients in China.
- Published
- 2024
- Full Text
- View/download PDF
16. Acquired Elliptocytosis as a Manifestation of Myelodysplastic Syndrome Associated with 20q Deletion
- Author
-
Amen Allah Nasr, Sawsen Bouzidi, Khaouala Bderi, Zeineb Ben Hassine, Samy Laayouni, Naouel Ben Salah, Najiba Fekih-Mrissa, Bassem Louzir, and Brahim Nsiri
- Subjects
20q deletion ,acquired elliptocytosis ,autoimmune diseases ,myelodysplastic syndrome ,sjögren’s syndrome ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Elliptocytes are most abundant in hereditary elliptocytosis. Isolated deletion 20q [del(20q)] associated with elliptocytosis in a patient with myelodysplastic syndrome (MDS) is very rare, and only a few cases are reported in the literature. This report describes a case of an MDS-related autoimmune disease (Sjögren’s syndrome) with acquired elliptocytosis and del(20q). We discuss their clonal relationship and del(20q) status in the process of disease progression. A 58-year-old woman, with a history of Sjögren’s syndrome, was admitted for investigation of pancytopenia. An initial evaluation revealed a regenerative normochromic normocytic anemia with hemoglobin of 9.2 g/dL, an absolute reticulocyte count elevated at 245 × 109/L, a platelet count of 70 × 109/L, white blood cells of 1.4 × 109/L, and polynuclear neutrophils (PNNs) at 0.64 × 109/L. A slightly elevated total bilirubin of 28 μmol/L prompted a hemolytic workup. A peripheral blood smear showed frequent elliptocytes and occasional spherocytes. In addition, the PNNs were hyposegmented and hypergranular. Bone marrow aspirate smears showed significant dysplasia of all hemopoietic lineages indicating a diagnosis of multilineage dysplasia. Cytogenetic analysis showed a 20q deletion. The IPSS-R score was 4, stratifying her to the intermediate-risk IPSS-R group. MDS is frequently associated with a variety of autoimmune disorders. Connective tissue diseases account for 25%–30% of MDS-related autoimmune diseases but Sjögren’s syndrome has been rarely reported.
- Published
- 2024
- Full Text
- View/download PDF
17. HALP score as a novel prognostic factor for patients with myelodysplastic syndromes
- Author
-
Vildan Gursoy, Sevil Sadri, Hatice Demirci Kucukelyas, Fazıl Cagri Hunutlu, Ibrahim Ethem Pinar, Zafer Serenli Yegen, Nihan Alkış, Tuba Ersal, Ridvan Ali, Vildan Ozkocaman, and Fahir Ozkalemkas
- Subjects
Albumin ,Hemoglobin ,Lymphocyte ,Myelodysplastic syndrome ,Platelet ,Prognostic factor ,Medicine ,Science - Abstract
Abstract Myelodysplastic syndrome (MDS) is a heterogeneous spectrum of clonal hematopoietic disorders with varying degrees of cytopenia and morphologic dysplasia. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is a prognostic marker in several types of malignant tumors. Prognostic value of HALP score remains unclear for MDS. To determine the prognostic value of baseline HALP score in MDS. We retrospectively analyzed data from 130 newly diagnosed MDS patients evaluated and classified under HALP score. By the receiver operating characteristic (ROC) analysis, the optimal cut-off value of HALP was > 67.5 in predicting mortality. Patients were divided into two groups: with low and high HALP scores, and the characteristics were compared between both groups. Patients’ median age was 68 (19–84) years, and 79 (60.8%) were male. Higher HALP score was detected in MDS patients with intermediate-risk under IPSS score, and at high and very high risks under IPSS-R score, and those receiving azacitidine (AZA) treatment. The survival rates of those with a HALP score > 67.5 were significantly lower than those with low HALP score at 17.77 ± 3.98 (median ± SE) (p 67.5 were found as 25, 18, and 11%, respectively. Median overall survival (OS) was also determined as 33.10 (95% CI 16.34–49.88) months by the Kaplan–Meier method. HALP score has shown an ability to be a useful prognostic biomarker in various cancers, including MDS. The meaningful cut-off value of HALP is disease-specific and largely study-specific. High HALP score is associated with unfavorable clinicopathological characteristics. Also, it may be useful in predicting OS and mortality of MDS.
- Published
- 2024
- Full Text
- View/download PDF
18. Effects of immune cells in mediating the relationship between gut microbiota and myelodysplastic syndrome: a bidirectional two-sample, two-step Mendelian randomization study
- Author
-
Zuxi Feng, Minjing Liao, Xuege Guo, Lijuan Li, and Liansheng Zhang
- Subjects
Myelodysplastic syndrome ,Gut microbiota ,Mendelian randomization ,Immunophenotypes ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background The definitive establishment of a causal relationship between gut microbiota and myelodysplastic syndrome (MDS) has not been achieved. Furthermore, the involvement of immune cells in mediating the connection between gut microbiota and MDS is presently unclear. Methods To elucidate the bidirectional correlation between gut microbiota and MDS, as well as to investigate the mediating role of immune cells, a bidirectional two-sample, two-step Mendelian randomization (MR) study was conducted. Summary statistics were obtained from genome-wide association studies (GWAS), including MDS (456,348 individuals), gut microbiota (18,340 individuals), and 731 immune cells signatures (3757 individuals). Results Genetically predicted eight gut microbiota traits were significantly associated with MDS risk, but not vice versa. Through biological annotation of host-microbiome shared genes, we found that immune regulation may mediate the impact of gut microbiota on MDS. Subsequently, twenty-three immunophenotypes that exhibited significant associations with MDS risk and five of these immunophenotypes were under the causal influence of gut microbiota. Importantly, the causal effects of gut microbiota on MDS were significantly mediated by five immunophenotypes, including CD4 +T cell %leukocyte, CD127 on CD45RA − CD4 not regulatory T cell, CD45 on CD33 + HLA DR + WHR, CD33 on basophil, and Monocyte AC. Conclusions Gut microbiota was causally associated with MDS risk, and five specific immunophenotypes served as potential causal mediators of the effect of gut microbiota on MDS. Understanding the causality among gut microbiota, immune cells and MDS is critical in identifying potential targets for diagnosis and treatment.
- Published
- 2024
- Full Text
- View/download PDF
19. Haemophagocytic lymphohistiocytosis caused by GATA2 deficiency: a report on three patients
- Author
-
Lin Wu, Jingshi Wang, Deli Song, Yahong You, and Zhao Wang
- Subjects
Haemophagocytic lymphohistiocytosis ,GATA2 ,EBV ,Nontuberculous mycobacterium ,Myelodysplastic syndrome ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Haemophagocytic lymphohistiocytosis (HLH) is a syndrome that occurs in patients with severe systemic hyperinflammation. GATA binding protein 2 (GATA2) is a transcription factor and key component in haematopoiesis and stem cell biology. Case presentation Three patients with HLH, one with Mycobacterium avium infection, one with Epstein–Barr virus (EBV) infection, and one with Mycobacterium kansasii infection, were all subsequently found to have a defect in the GATA2 gene through genetic testing. Conclusions GATA2 deficiency syndrome should be considered in patients with myelodysplastic syndrome, nontuberculous mycobacterium infection and HLH. In addition, the GATA2 gene variant may be a genetic defect that could be the cause of the primary HLH. However, further studies are needed to confirm the role of GATA2 pathogenic variants in the pathogenesis of HLH.
- Published
- 2024
- Full Text
- View/download PDF
20. A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms
- Author
-
Rami Abdulbaki and Sheeja T. Pullarkat
- Subjects
myelodysplastic neoplasms ,myelodysplastic syndrome ,next-generation sequencing ,molecular features ,myelodysplastic syndrome with germline predisposition syndromes ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Myelodysplastic neoplasm (MDS) is a heterogeneous group of clonal hematological disorders that originate from the hematopoietic and progenitor cells and present with cytopenias and morphologic dysplasia with a propensity to progress to bone marrow failure or acute myeloid leukemia (AML). Genetic evolution plays a critical role in the pathogenesis, progression, and clinical outcomes of MDS. This process involves the acquisition of genetic mutations in stem cells that confer a selective growth advantage, leading to clonal expansion and the eventual development of MDS. With the advent of next-generation sequencing (NGS) assays, an increasing number of molecular aberrations have been discovered in recent years. The knowledge of molecular events in MDS has led to an improved understanding of the disease process, including the evolution of the disease and prognosis, and has paved the way for targeted therapy. The 2022 World Health Organization (WHO) Classification and the International Consensus Classification (ICC) have incorporated the molecular signature into the classification system for MDS. In addition, specific germline mutations are associated with MDS development, especially in pediatrics and young adults. This article reviews the genetic abnormalities of MDS in adults with a brief review of germline predisposition syndromes.
- Published
- 2024
- Full Text
- View/download PDF
21. High PD-L1 expression is associated with unfavorable clinical features in myelodysplastic neoplasms
- Author
-
Leticia Rodrigues Sampaio, Mateus de Aguiar Viana, Vanessa Silva de Oliveira, Bruna Vitoriano Ferreira, Mayara Magna Lima Melo, Roberta Taiane Germano de Oliveira, Daniela de Paula Borges, Silvia Maria Meira Magalhãesa, and Ronald F. Pinheiro
- Subjects
Protein death ligand 1 ,Dyserythropoiesis ,Immune evasion ,Myelodysplastic syndrome ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstatct: Introduction: Immune checkpoints are regulators of the immune system response that allow self-tolerance. Molecules such as Programmed Cell Death Protein 1 (PD-1) and its Ligand (PD-L1) participate in the immune checkpoint by signaling co-inhibition of lymphocyte responses. In cancers, PD-L1 expression is associated with the immune evasion mechanism, which favors tumor growth. The use of anti-PD-1/PD-L1 drugs is already well described in solid tumors, but still not fully understood in hematologic malignancies. Myelodysplastic neoplasms (MDSs) are heterogeneous bone marrow disorders with an increased risk of progression to Acute Myeloid Leukemia (AML). The MDS affects hematopoietic stem cells and its pathogenesis is linked to genetic and epigenetic defects, in addition to immune dysregulation. The influence of the PD-L1 on the MDS remains unknown. Methods: In this study, we evaluated the mRNA expression of the PD-L1 in 53 patients with MDS, classified according to the WHO 2016 Classification. Results: Patients with dyserythropoiesis presented significantly higher PD-L1 expression than patients without dyserythropoiesis (p = 0.050). Patients classified as having MDS with an excess of blasts 2 (MDS-EB2) presented a significant upregulation in the mRNA expression of the PD-L1 compared to the MDS with an excess of blasts 1 (MDS-EB1) (p = 0.050). Furthermore, we detected three patients with very high levels of PD-L1 expression, being statistically classified as outliers. Conclusion: We suggested that the high expression of the PD-L1 is associated with a worse prognosis in the MDS and functional studies are necessary to evaluate the possible use of anti-PD-L1 therapies for high-risk MDS, such as the MDS-EBs.
- Published
- 2024
- Full Text
- View/download PDF
22. Comparative analysis of feature-based ML and CNN for binucleated erythroblast quantification in myelodysplastic syndrome patients using imaging flow cytometry data
- Author
-
Carina A. Rosenberg, Matthew A. Rodrigues, Marie Bill, and Maja Ludvigsen
- Subjects
Imaging flow cytometry ,Artificial intelligence ,Feature-based machine learning ,Convolutional neural network ,Dyserythropoiesis ,Myelodysplastic syndrome ,Medicine ,Science - Abstract
Abstract Myelodysplastic syndrome is primarily characterized by dysplasia in the bone marrow (BM), presenting a challenge in consistent morphology interpretation. Accurate diagnosis through traditional slide-based analysis is difficult, necessitating a standardized objective technique. Over the past two decades, imaging flow cytometry (IFC) has proven effective in combining image-based morphometric analyses with high-parameter phenotyping. We have previously demonstrated the effectiveness of combining IFC with a feature-based machine learning algorithm to accurately identify and quantify rare binucleated erythroblasts (BNEs) in dyserythropoietic BM cells. However, a feature-based workflow poses challenges requiring software-specific expertise. Here we employ a Convolutional Neural Network (CNN) algorithm for BNE identification and differentiation from doublets and cells with irregular nuclear morphology in IFC data. We demonstrate that this simplified AI workflow, coupled with a powerful CNN algorithm, achieves comparable BNE quantification accuracy to manual and feature-based analysis with substantial time savings, eliminating workflow complexity. This streamlined approach holds significant clinical value, enhancing IFC accessibility for routine diagnostic purposes.
- Published
- 2024
- Full Text
- View/download PDF
23. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
- Author
-
Daniel Karel, Claire Valburg, Navitha Woddor, Victor E. Nava, and Anita Aggarwal
- Subjects
myelodysplastic neoplasm ,myelodysplastic syndrome ,MDS ,precision medicine ,targeted therapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Myelodysplastic neoplasms (MDS) are a heterogenous clonal disorder of hemopoietic stem cells characterized by cytomorphologic dysplasia, ineffective hematopoiesis, peripheral cytopenias and risk of progression to acute myeloid leukemia (AML). Our understanding of this disease has continued to evolve over the last century. More recently, prognostication and treatment have been determined by cytogenetic and molecular data. Specific genetic abnormalities, such as deletion of the long arm of chromosome 5 (del(5q)), TP53 inactivation and SF3B1 mutation, are increasingly associated with disease phenotype and outcome, as reflected in the recently updated fifth edition of the World Health Organization Classification of Hematolymphoid Tumors (WHO5) and the International Consensus Classification 2022 (ICC 2022) classification systems. Treatment of lower-risk MDS is primarily symptom directed to ameliorate cytopenias. Higher-risk disease warrants disease-directed therapy at diagnosis; however, the only possible cure is an allogenic bone marrow transplant. Novel treatments aimed at rational molecular and cellular pathway targets have yielded a number of candidate drugs over recent years; however few new approvals have been granted. With ongoing research, we hope to increasingly offer our MDS patients tailored therapeutic approaches, ultimately decreasing morbidity and mortality.
- Published
- 2024
- Full Text
- View/download PDF
24. Molecular genetic characterization of myeloid neoplasms with idic(X)(q13) and i(X)(q10)
- Author
-
Marta Brunetti, Kristin Andersen, Gunhild Trøen, Francesca Micci, Signe Spetalen, Andrea Lenartova, Maren Randi Tandsæther, and Ioannis Panagopoulos
- Subjects
acute myeloid leukemia ,myelodysplastic syndrome ,cytogenetics ,idic(X)(q13) ,i(X)(q10) ,array comparative genomic hybridization ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background/AimIsodicentric [idic(X)(q13)] and isochromosome [i(X)(q10)] are infrequent aberrations in neoplastic diseases. The former is mainly reported in elderly women with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), whereas the latter is mostly found as a secondary aberration or part of complex karyotypes in various types of neoplasms, including MDS and AML. Here, we present the molecular genetics and clinical features of six patients with myeloid neoplasia and the above-mentioned aberrations.Patients and MethodsArray comparative genome hybridization (aCGH) and next-generation sequencing (NGS) myeloid panel were used to examine genetic alterations in five bone marrow samples containing neoplastic cells carrying idic(X)(q13) and one sample with i(X)(q10).ResultsThe breakpoints of idic(X)(q13) were clustered within a 200 kbp region encompassing FAM236B, DMRTC1B, and DMRTC1. The breakpoint of i(X)(q10) was identified within a 112 kbp region on sub-band p11.22 containing SSX2, SSX2B, and SPANXN5. Pathogenic variants of TET2 were identified in four cases, SF3B1 in three cases, ASXL1 and SRSF2 in two cases each, whereas STAG2, RUNX1, U2AF1, and TP53 pathogenic variants were detected in only single cases.ConclusionsThe breakpoints of idic(X)(q13) are within a 200kbp. i(X)(q10) in our study turned out to be a cryptic idic(X)(p11) aberration, reported for the first time here. TET2, SF3B1, ASXL1, or SRSF2 were highly prevalent in patients with idic(X)(q13)/i(X)(q10) abnormalities and were often associated with a worse prognosis.
- Published
- 2024
- Full Text
- View/download PDF
25. Impact of platelet transfusion refractoriness in the first 30 days post-hematopoietic stem cell transplantation on outcomes of patients with myelodysplastic syndrome
- Author
-
Yuanfeng Zhang, Yan Wang, Runzhi Ma, Li Liu, Jiali Sun, Xin Chen, Donglin Yang, Aiming Pang, Rongli Zhang, Qiaoling Ma, Weihua Zhai, Yi He, Jialin Wei, Tingting Zhang, Erlie Jiang, MingZhe Han, and Sizhou Feng
- Subjects
myelodysplastic syndrome ,transplantation ,platelet transfusion refractoriness ,stem ,cell ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionCurrently, no study has determined whether platelet transfusion refractoriness (PTR) post-hematopoietic stem cell transplantation (HSCT) before engraftment in patients with myelodysplastic syndrome (MDS) would impacts clinical outcomes.MethodsWe performed a MDS-specific retrospective analysis to determine whether PTR in one-month post-HSCT in patients with MDS could influence outcomes.Results and discussionAmong the 315 patients enrolled, 110 (34.9 %) had PTR from stem cell infusion to one-month post-HSCT. Baseline characteristics of the PTR and non-PTR groups were similar. We found that patients with PTR had a slower and lower rate of platelet engraftment by day 28, as well as a slower recovery of neutrophils. The median days of neutrophil and platelet engraftment were 14 days (9-23) and 17 days (8-28) in the PTR groups versus 13 days (9-23) and 15 days (7-28) in the non-PTR group (P1041ng/ml (median level) were independent adverse factors of platelet engraftment.
- Published
- 2024
- Full Text
- View/download PDF
26. Immune‐dysregulation harnessing in myeloid neoplasms
- Author
-
Mohammad Jafar Sharifi, Ling Xu, Nahid Nasiri, Mehnoosh Ashja‐Arvan, Hadis Soleimanzadeh, and Mazdak Ganjalikhani‐Hakemi
- Subjects
acute myeloid leukemia ,myelodysplastic syndrome ,myeloproliferative disorders ,tumor‐infiltrating immune cells ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Myeloid malignancies arise in bone marrow microenvironments and shape these microenvironments in favor of malignant development. Immune suppression is one of the most important stages in myeloid leukemia progression. Leukemic clone expansion and immune dysregulation occur simultaneously in bone marrow microenvironments. Complex interactions emerge between normal immune system elements and leukemic clones in the bone marrow. In recent years, researchers have identified several of these pathological interactions. For instance, recent works shows that the secretion of inflammatory cytokines such as tumor necrosis factor‐α (TNF‐α), from bone marrow stromal cells contributes to immune dysregulation and the selective proliferation of JAK2V617F+ clones in myeloproliferative neoplasms. Moreover, inflammasome activation and sterile inflammation result in inflamed microenvironments and the development of myelodysplastic syndromes. Additional immune dysregulations, such as exhaustion of T and NK cells, an increase in regulatory T cells, and impairments in antigen presentation are common findings in myeloid malignancies. In this review, we discuss the role of altered bone marrow microenvironments in the induction of immune dysregulations that accompany myeloid malignancies. We also consider both current and novel therapeutic strategies to restore normal immune system function in the context of myeloid malignancies.
- Published
- 2024
- Full Text
- View/download PDF
27. Acquired erythropoietic protoporphyria secondary to myelodysplastic syndrome: from mythology to oncologyAcquired Erythropoietic Protoporphyria Secondary to Myelodysplastic Syndrome: From Mythology to Oncology
- Author
-
Mirjana Urosevic-Maiwald, Jivko Kamarachev, Christoph Renner, and Anna-Elisabeth Minder
- Subjects
Porphyria ,myelodysplastic syndrome ,photosensitivity ,erythropoietic protoporphyria ,Dermatology ,RL1-803 - Abstract
Abstract is missing (Short communication)
- Published
- 2024
- Full Text
- View/download PDF
28. Trisomy 8 presentation by inflammatory manifestations and its response to thalidomide: two case reports and narrative review
- Author
-
Xiaohua Zhang, Yan Zhao, Yuting Pan, Jing Jin, Zhidan Fan, and Haiguo Yu
- Subjects
trisomy 8 ,Behcet’s disease ,myelodysplastic syndrome ,thalidomide ,gastrointestinal involvement ,Pediatrics ,RJ1-570 - Abstract
ObjectiveIt has been recognized that there is a nexus among Trisomy 8 (T8), Behcet's disease (BD), and myelodysplastic syndrome (MDS). We reported a series of inflammatory features in 2 children with T8 without hematological involvement.Methods2 children with trisomy 8 who were excluded from MDS were retrospectively collected from the Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical University, Nanjing.ResultsPatients developed a range of inflammatory manifestations before a diagnosis of T8. The clinical manifestations of T8 patients vary from normal to severely disabled. Glucocorticoids and thalidomide can effectively relieve inflammation in patients with T8.ConclusionThe early clinical manifestations of T8 in children lack specificity, and the diagnosis is mainly based on karyotype analysis, gastrointestinal endoscopy and bone marrow aspiration findings. Active and effective immunoregulatory therapy and long-term follow-up can improve the prognosis of patients with T8.
- Published
- 2024
- Full Text
- View/download PDF
29. Noninflammatory extrafacial edema as a clue to the diagnosis of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome
- Author
-
Michael J. Diaz, BS, Vivian Y. Liu, MD, and Kiran Motaparthi, MD
- Subjects
extrafacial edema ,myelodysplastic syndrome ,periorbital edema ,Sweet syndrome ,systemic inflammation ,treatment-refractory ,Dermatology ,RL1-803 - Published
- 2024
- Full Text
- View/download PDF
30. Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or SF3B1 Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart Review
- Author
-
Shamim Mortuza, Benjamin Chin-Yee, Tyler E. James, Ian H. Chin-Yee, Benjamin D. Hedley, Jenny M. Ho, Lalit Saini, Alejandro Lazo-Langner, Laila Schenkel, Pratibha Bhai, Bekim Sadikovic, Jonathan Keow, Nikhil Sangle, and Cyrus C. Hsia
- Subjects
myelodysplastic syndrome ,MDS ,ring sideroblasts ,molecular pathology ,next-generation sequencing ,SF3B1 mutation ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Myelodysplastic neoplasms (MDS) with ring sideroblasts (RS) are diagnosed via bone marrow aspiration in the presence of either (i) ≥15% RS or (ii) 5–14% RS and an SF3B1 mutation. In the MEDALIST trial and in an interim analysis of the COMMANDS trial, lower-risk MDS-RS patients had decreased transfusion dependency with luspatercept treatment. A total of 6817 patients with suspected hematologic malignancies underwent molecular testing using a next-generation-sequencing-based genetic assay and 395 MDS patients, seen at our centre from 1 January 2018 to 31 May 2023, were reviewed. Of these, we identified 39 evaluable patients as having lower-risk MDS with SF3B1 mutations: there were 20 (51.3%) males and 19 (48.7%) females, with a median age of 77 years (range of 57 to 92). Nineteen (48.7%) patients had an isolated SF3B1 mutation with a mean variant allele frequency of 35.2% +/− 8.1%, ranging from 7.4% to 46.0%. There were 29 (74.4%) patients with ≥15% RS, 6 (15.4%) with 5 to 14% RS, one (2.6%) with 1% RS, and 3 (7.7%) with no RS. Our study suggests that a quarter of patients would be missed based on the morphologic criterion of only using RS greater than 15% and supports the revised 2022 definitions of the World Health Organization (WHO) and International Consensus Classification (ICC), which shift toward molecularly defined subtypes of MDS and appropriate testing.
- Published
- 2024
- Full Text
- View/download PDF
31. Angioinvasive Mucormycosis Mimicking Mass and Pulmonary Thromboembolism in a Patient with Myelodysplastic Syndrome: A Case Report
- Author
-
Hyo Ju Na, Song Soo Kim, Shinhye Cheon, Jin Hwan Kim, and Hyeyoung Kwon
- Subjects
pulmonary mucormycosis ,angioinvasive mucormycosis ,myelodysplastic syndrome ,computed tomography ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Mucormycosis encompasses a range of fungal infections that can impact various organs. Although pulmonary mucormycosis is relatively rare, it poses a significant threat, particularly to individuals with compromised immune systems. Pulmonary mucormycosis presents with various radiological manifestations. Notably, the involvement of the angioinvasive pulmonary artery in pulmonary mucormycosis cases has seldom been documented. In this report, we showcase the radiological characteristics of angioinvasive mucormycosis, which can mimic pulmonary thromboembolism or a pulmonary artery tumor, in a patient diagnosed with myelodysplastic syndrome.
- Published
- 2024
- Full Text
- View/download PDF
32. Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine
- Author
-
Eri Takada, Nobuhiko Nakamura, Yuto Kaneda, Kenji Fukuno, Shin Lee, Kei Fujita, Tetsuji Morishita, Yoshikazu Ikoma, Takuro Matsumoto, Hiroshi Nakamura, Junichi Kitagawa, Nobuhiro Kanemura, Senji Kasahara, Takeshi Hara, Hisashi Tsurumi, and Masahito Shimizu
- Subjects
myelodysplastic syndrome ,azacitidine ,skeletal muscle depletion ,hematological toxicity ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Background: Azacitidine (AZA) is the standard treatment for patients with high-risk myelodysplastic syndromes (MDS). The impact of skeletal muscle depletion (SMD), which is associated with outcomes of hematological malignancies, on the clinical course of MDS patients treated with AZA was investigated. Methods: This retrospective, observational study included 50 MDS patients treated with AZA. Muscle mass was evaluated using the skeletal muscle index (SMI), which is the area of muscle mass at the third lumbar vertebra on CT images divided by the square of the height. Results: Of the enrolled patients, 39 were males, and their median age was 69.5 years. Twenty-seven (20 male and 7 female) patients showed SMD. The median survival was 13.4 months in the SMD group and 15.2 months in the non-SMD group, with no significant difference and no significant association between the response rate or severe non-hematological toxicities and the presence of SMD. By contrast, grade 3–4 anemia and thrombocytopenia were significantly more frequent in the SMD group than in the non-SMD group. SMD was associated with severe anemia and thrombocytopenia in MDS patients treated with AZA. Conclusion: Reduced skeletal muscle mass may predict severe hematological toxicity in MDS patients treated with AZA.
- Published
- 2024
- Full Text
- View/download PDF
33. MYELODYSPLASTIC SYNDROME NOT OTHERWISE CLASSIFIED. DO AUTOMATIC METHODS CORRELATE WITH THE MICROSCOPIC METHOD OF BLOOD SMEAR ASSESSMENT?
- Author
-
Milena Małecka-Giełdowska, Katarzyna Poreda, Agata Skwarek, and Michalina Lulek
- Subjects
pancytopenia ,myelodysplastic syndrome ,blood smear ,complete blood count ,lymphocytes ,Medicine - Abstract
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal malignancies of the hematopoietic system, characterized by ineffective hematopoiesis with peripheral cytopenias. The aim of the study was to detect differences between automatic leukocyte separation and microscopic evaluation of a blood smear in a patient with MDS. A 68-year-old patient with a history of MDS pancytopenia and vascular bleeding diathesis was admitted to the Department of Internal Diseases and Endocrinology of the University Clinical Centre of the Medical University of Warsaw. The patient was diagnosed with metabolic alkalosis, renal failure and hyperparathyroidism. Morphological examinations showed persistent pancytopenia. The microscopic evaluation of the blood smear showed features of dysplasia, e.g. asynchrony of nucleus/cytoplasm maturation, hypogranulation of the granulocyte cytoplasm, unequal distribution of granules in the cytoplasm, and hyposegmentation in neutrophils. Complete blood count and blood smear were presented as percentages obtained from automatic leukocyte separation and microscopic smear evaluation of three consecutive patient examinations, respectively. The largest discrepancies were in the proportion of eosinophils (0.6%/1.3%/0% vs. 29.5%/26.0%/9.0%), neutrophils (49.7%/41.7%/32.4% vs 26.0%/13.6%/22.0%) and atypical lymphocytes (4.4%/2.9% vs 2.4%/5.0%). Microscopic analysis also showed the presence of eosinophils at various stages of maturation (eosinophilic myelocytes). Automatic blood smear analysis compared to manual analysis can show significantly different results. To diagnose diseases of the hematopoietic system, it is recommended to verify the results of the tests using the microscopic method. Bone marrow cytogenetic and molecular tests can also be performed as an auxiliary.
- Published
- 2024
- Full Text
- View/download PDF
34. Extensive reactive cutaneous histiocytic infiltrate resembling non-Langerhans cell histiocytosis as the presenting sign of underlying vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome
- Author
-
Cynthia X. Wang, MD, MPHS, Christine C. Yokoyama, MD, PhD, Ilana S. Rosman, MD, and Amy C. Musiek, MD
- Subjects
autoinflammatory ,hematology ,histiocytosis ,myelodysplastic syndrome ,oncology ,somatic ,Dermatology ,RL1-803 - Published
- 2024
- Full Text
- View/download PDF
35. Multicentral Retrospective Analysis of Venetoclax-Based Treatments in AML and MDS: A Real-World Study by the Turkish Hematology Network Group
- Author
-
Ibrahim Halil Acar, Muzeyyen Aslaner Ak, Gulsah Akyol, Taha Ulutan Kars, Yildiz Ipek, Ayse Uysal, Figen Atalay, Aysun Senturk Yikilmaz, Omer Ekinci, Idris Ince, Birgul Onec, Hakan Keski, Mufide Okay Ozgeyik, Sebnem Izmir Guner, Esra Terzi Demirsoy, Oktay Bilgir, and Birol Guvenc
- Subjects
acute myeloid leukemia ,myelodysplastic syndrome ,venetoclax ,treatment outcome ,malignancy ,Medicine (General) ,R5-920 - Abstract
Background and Objectives: Acute myeloid leukemia and myelodysplastic syndrome are both clonal hematologic malignancies that primarily affect older adults. Current treatments for AML/MDS are both limited in number and efficacy. This study aims to evaluate venetoclax-based therapies in AML/MDS, focusing on overall survival and recurrence-free survival rates, and to expand real-world data on its use. Materials and Methods: Clinical and laboratory data on patients with AML/MDS aged 18≥ treated with venetoclax between January 2019 and July 2022 were included. Survival analysis was calculated based on the period from 2019 to December 2023. Results: A total of 161 AML and 40 patients with MDS were included. The median age was 63.53 ± 15.30 years for AML and 70.12 ± 10.21 years for MDS. In both groups, over 55% are male. A total of 77.6% of patients with AML and 75% of patients with MDS received treatment prior to venetoclax. Venetoclax was administered in combination with azacitidine to 84.5% of AML and 67.5% of MDS. The relapse rate in AML is approximately 15%. Overall, the 2-year survival rate is 46% and 18.73 months. The overall CR/CRi rate for patients with AML is 49.1%, while for patients with MDS, it is 50%. The 2-year survival rate for patients with MDS is 52.7%. The 2-year RFS rate was 75.5% for AML and 90.9% for MDS. The relapse rate in AML is approximately 15%. The percentage of adverse events leading to treatment discontinuation among those with grade 3–4 toxicity is low; 26.7% for AML (n = 43) and 15% for MDS (n = 6). Conclusions: Our real-world data demonstrate that venetoclax has the potential to improve overall survival rates when used in combination with HMAs and supports its use in patients with AML/MDS.
- Published
- 2024
- Full Text
- View/download PDF
36. Treatment of perianal infection in a patient with myelodysplastic syndrome
- Author
-
Shijiang Zhong, Ting You, Wei Wang, and You Li
- Subjects
Myelodysplastic syndrome ,Perianal infection ,Influence factors ,Surgery ,RD1-811 - Published
- 2024
- Full Text
- View/download PDF
37. Cranial hypertrophic pachymeningitis with myelodysplastic syndrome
- Author
-
Shohei Kikuchi, Tomohiro Hayashi, Honoka Nitta, Yusuke Kamihara, Akinori Wada, Tomoki Minemura, Yoshimi Nabe, Jun Murakami, Yuji Nakatsuji, and Tsutomu Sato
- Subjects
Hypertrophic pachymeningitis ,Myelodysplastic syndrome ,Steroids therapy ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Hypertrophic pachymeningitis (HP) is a rare inflammatory disease characterized by thickening of the dura mater. HP develops with several inflammatory diseases. Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and IgG4 related disease are reported as 2 major causes. With hematologic diseases, only 3 cases have been reported. We report the case of myelodysplastic syndrome (MDS) developing HP. Our case provides a thought-provoking hypothesis regarding the potential relationship between MDS and HP.
- Published
- 2024
- Full Text
- View/download PDF
38. A case report of secondary B-cell acute lymphoblastic leukemia treated with a combination of FLT3 inhibitor and decitabine
- Author
-
Mengci Hu, Wenzhe Li, Pan Li, Jie Tan, and Ya Wang
- Subjects
diffuse large B-cell lymphoma ,acute lymphoblastic leukemia ,secondary acute lymphoblastic leukemia ,FLT3 ,myelodysplastic syndrome ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Secondary acute lymphoblastic leukemia (s-ALL) refers to acute lymphoblastic leukemia that occurs after a previous malignant tumor, including therapy-related acute lymphoblastic leukemia (t-ALL) and prior malignant tumor acute lymphoblastic leukemia (pm-ALL). We report a case of a 51-year-old female patient who developed acute lymphoblastic leukemia 14 years after being diagnosed with diffuse large B-cell lymphoma (DLBCL). The patient was unresponsive to conventional chemotherapy for acute lymphoblastic leukemia (ALL) and achieved remission with a combination of sorafenib and decitabine based on the molecular biology characteristics of her B-ALL.
- Published
- 2024
- Full Text
- View/download PDF
39. Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review
- Author
-
Polina Bellman, Jesus D. Gonzalez-Lugo, Moazzam Shahzad, Muhammad Kashif Amin, Muhammad Fareed Khalid, Nahid Suleman, Nausheen Ahmed, Anurag K. Singh, Abdulraheem Yacoub, Da Zhang, Joseph P. McGuirk, and Muhammad Umair Mushtaq
- Subjects
myelodysplastic syndrome ,VEXAS syndrome ,outcomes ,allogeneic hematopoietic stem cell transplantation ,fludarabine and cyclophosphamide ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Vacuoles, E1 syndrome, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a chronic inflammatory disorder that affects various organ systems. It is associated with hematologic malignancies and is generally refractory to therapies. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be considered for selected patients. We report a case wherein systemic and hematological manifestations completely resolved in a patient with VEXAS and associated myelodysplastic syndrome (MDS), following the administration of fludarabine and cyclophosphamide as part of the preparation for allo-HSCT. We conducted a systematic literature review and included 86 patients with VEXAS syndrome and associated MDS. Most cases presented with musculoskeletal involvement (71%) and anemia (72%) with lower-risk MDS. Most patients responded to corticosteroids (CS) but had a recurrence of symptoms with CS taper and were refractory to other immunosuppressive agents. Hypomethylating agents and Janus kinase inhibitors achieved a complete response in some cases. Further research is needed to develop more effective treatment strategies.
- Published
- 2024
- Full Text
- View/download PDF
40. VEXAS syndrome: on the threshold of changing perceptions of known diseases
- Author
-
B. D. Chaltsev, A. V. Torgashina, A. M. Lila, T. V. Markova, S. I. Kutsev, O. P. Ryzhkova, A. A. Orlova, A. V. Kokhno, T. I. Solovyova, V. N. Dvirnyk, A. M. Kovrigina, T. N. Obukhova, E. N. Parovichnikova, and E. L. Nasonov
- Subjects
vexas syndrome ,macrocytic anemia ,vasculitis ,relapsing polychondritis ,neutrophilic dermatosis ,vacuolization of bone marrow cells ,myelodysplastic syndrome ,Medicine - Abstract
This article presents the first case of VEXAS syndrome identified in the Russian Federation as well as characteristics of currently known clinical manifestations and treatment approaches. The clinical observation described is an impressive example of how the identification of a new pathogenic mutation can change the understanding of the classification, diagnosis and treatment of previously known immunoinflammatory diseases. Thus, in refractory forms of relapsing polychondritis, neutrophilic dermatosis, atypical forms of vasculitis, inflammatory joint diseases or undifferentiated systemic inflammatory syndrome, especially when associated with macrocytic anemia and myelodysplastic syndrome, VEXAS syndrome should be suspected and genetic testing should be performed to exclude the autoinflammatory nature of the existing condition.
- Published
- 2023
- Full Text
- View/download PDF
41. Features of the clinical picture and course of GATA2 deficiency complicated by generalized verrucosis with an outcome in myelodysplastic syndrome in adulthood
- Author
-
E. A. Frolov, F. I. Abdulaeva, U. A. Gornostaeva, T. V. Latysheva, E. A. Latysheva, and G. E. Aminova
- Subjects
primary immunodeficiency ,generalized verrucosis ,myelodysplastic syndrome ,hematopoietic stem cell transplantation ,Medicine (General) ,R5-920 - Abstract
GATA2 deficiency is a rare disease belonging to the group of phagocyte birth defects, which is clinically manifested by four syndromes: MonoMac syndrome (myedysplasia and immunodeficiency associated with the development of infections caused by Mycobacterium avium complex); monocyte, dendritic cell, B- and NK-lymphocyte deficiency syndrome; Emberger syndrome, including primary lymphedema with myelodysplasia and sensorineural hearing loss, as well as familial myelodysplastic syndrome and acute myeloid leukemia. The disease is inherited by autosomal dominant type, but in most cases, mutations ofthe germ line of the GATA2 gene occur de novo. The first manifestations of the disease occur in early adulthood, the course of GATA2 deficiency is variable and may differ in individuals in the same family with similar genetic variants. The article presents a clinical case of manifestation of GATA2 deficiency at the age of seven years in the form of development of generalized verrucosis, lymphostasis of the lower limb, generalized tuberculosis with involvement of the abdominal cavity, small pelvis, and chest organs. The examination revealed deficiency of monocytes, B- and NK-lymphocytes, myelodysplastic syndrome with multilineage dysplasia. We present a detailed description of the clinical picture and peculiarities of the course of the primary immunodeficiency state, the results of the examination and treatment.
- Published
- 2023
- Full Text
- View/download PDF
42. TNFα induces Caspase-3 activity in hematopoietic progenitor cells CD34+, CD33+, and CD41 + of myelodysplastic syndromes
- Author
-
Anggraini Iriani, Andhika Rachman, Rahayuningsih D. Setiabudy, Siti B. Kresno, Aru W. Sudoyo, Mansyur Arief, Alida R. Harahap, and Marsya Kaila Fatina
- Subjects
Myelodysplastic syndrome ,TNFα ,caspase-3 ,CD34+ ,CD33+ ,CD41+ ,Cytology ,QH573-671 - Abstract
Abstract Background Cytopenia is the primary feature of Myelodysplastic Syndrome, even in the presence of hypercellular bone marrow. TNFα is recognized as both a proinflammatory, and proapoptotic cytokine with a well established role in promoting apoptosis in MDS. Therefore, TNFα has the potential to be a valuable biomarker for predicting the progression of cytopenia in MDS. This study aims to establish the role of TNFα exposure in triggering apoptosis through caspase-3 activity in CD34+, CD33+, and CD41 + cells in MDS. Methods This study is an in vitro comparative experimental research. Bone marrow mononuclear cells were isolated as the source of hematopoietic progenitor cells. Subsequently, CD34+, CD33+, and CD41 + cells were exposed to rhTNFα, and the caspase-3 activity was measured using flowcytometry. Results In MDS CD33 + and CD41 + caspase-3 activity of rhTNFα exposed cells was significantly higher than without exposed cells. The opposite result was found in CD34 + cells, where the caspase-3 activity without rhTNFα exposed cells was significantly higher than rhTNFα exposed cells. Conclusion rhTNFα exposure led to an elevation in caspase-3 activity in MDS progenitor cells, especially in those that had differentiated into myeloid cell CD33 + and megakaryocyte cell CD41+, as opposed to the early progenitor cells CD34+.
- Published
- 2023
- Full Text
- View/download PDF
43. Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions
- Author
-
Shyam A. Patel, Jan Cerny, William K. Gerber, Muthalagu Ramanathan, Asiri Ediriwickrema, Benjamin Tanenbaum, Lloyd Hutchinson, Xiuling Meng, Julie Flahive, Bruce Barton, Andrew J. Gillis‐Smith, Sakiko Suzuki, Salwa Khedr, William Selove, Anne W. Higgins, Patricia M. Miron, Karl Simin, Bruce Woda, and Jonathan M. Gerber
- Subjects
TP53 ,myelodysplastic syndrome ,acute myeloid leukemia ,hematopoietic stem cell ,clonal dynamics ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstract TP53 aberrations constitute the highest risk subset of myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The International Consensus Classification questions the blast threshold between MDS and AML. In this study, we assess the distinction between MDS and AML for 76 patients with TP53 aberrations. We observed no significant differences between MDS and AML regarding TP53 genomics. Median overall survival (OS) was 223 days for the entire group, but prognostic discrimination within subgroups showed the most inferior OS (46 days) for AML with multihit allelic state plus TP53 variant allele frequency (VAF) > 50%. In multivariate analysis, unadjusted Cox models revealed the following variables as independent risk factors for mortality: AML (vs. MDS) (hazard ratio [HR]: 2.50, confidence interval [CI]: 1.4–4.4, p = 0.001), complex karyotype (HR: 3.00, CI: 1.4–6.1, p = 0.003), multihit status (HR: 2.30, CI 1.3–4.2, p = 0.005), and absence of hematopoietic cell transplant (HCT) (HR: 3.90, CI: 1.8–8.9, p = 0.0009). Clonal dynamic modeling showed a significant reduction in TP53 VAF with front‐line hypomethylating agents. These findings clarify the impact of specific covariates on outcomes of TP53‐aberrant myeloid neoplasms, irrespective of the diagnosis of MDS versus AML, and may influence HCT decisions.
- Published
- 2023
- Full Text
- View/download PDF
44. Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms
- Author
-
Ashikh A. Seethy, Karthikeyan Pethusamy, Tushar Kushwaha, Gaurav Kumar, Joyeeta Talukdar, Rekha Chaubey, Udayakumar Dharmalingam Sundaram, Manoranjan Mahapatra, Renu Saxena, Ruby Dhar, Krishna K. Inampudi, and Subhradip Karmakar
- Subjects
Myelodysplastic neoplasms ,Myelodysplastic syndrome ,AML-myelodysplasia related ,Acute myeloid leukemia with myelodysplasia related changes ,Epigenetics ,TET2 protein ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Myelodysplastic Neoplasms (MDS) are clonal stem cell disorders characterized by ineffective hematopoiesis and progression to acute myeloid leukemia, myelodysplasia-related (AML-MR). A major mechanism of pathogenesis of MDS is the aberration of the epigenetic landscape of the hematopoietic stem cells and/or progenitor cells, especially DNA cytosine methylation, and demethylation. Data on TET2, the predominant DNA demethylator of the hematopoietic system, is limited, particularly in the MDS patients from India, whose biology may differ since these patients present at a relatively younger age. We studied the expression and the variants of TET2 in Indian MDS and AML-MR patients and their effects on 5-hydroxymethyl cytosine (5-hmC, a product of TET2 catalysis) and on the prognosis of MDS patients. Results Of the 42 MDS patients, cytogenetics was available for 31 sub-categorized according to the Revised International Prognostic Scoring System (IPSS-R). Their age resembled that of the previous studies from India. Bone marrow nucleated cells (BMNCs) were also obtained from 13 patients with AML-MR, 26 patients with de-novo AML, and 11 subjects with morphologically normal bone marrow. The patients had a significantly lower TET2 expression which was more pronounced in AML-MR and the IPSS-R higher-risk MDS categories. The 5-hmC levels in higher-risk MDS and AML-MR correlated with TET2 expression, suggesting a possible mechanistic role in the loss of TET2 expression. The findings on TET2 and 5-hmC were also confirmed at the tissue level using immunohistochemistry. Pathogenic variants of TET2 were found in 7 of 24 patient samples (29%), spanning across the IPSS-R prognostic categories. One of the variants – H1778R – was found to affect local and global TET2 structure when studied using structural predictions and molecular dynamics simulations. Thus, it is plausible that some pathogenic variants in TET2 can compromise the structure of TET2 and hence in the formation of 5-hmC. Conclusions IPSS-R higher-risk MDS categories and AML-MR showed a reduction in TET2 expression, which was not apparent in lower-risk MDS. DNA 5-hmC levels followed a similar pattern. Overall, a decreased TET2 expression and a low DNA 5-hmC level are predictors of advanced disease and adverse outcome in MDS in the population studied, i.e., MDS patients from India.
- Published
- 2023
- Full Text
- View/download PDF
45. Refractory Intestinal Behçet-Like Disease Associated with Trisomy 8 Myelodysplastic Syndrome Resolved by Parenteral Nutrition
- Author
-
Ryo Takahashi, Yasuo Matsubara, Satoshi Takahashi, Kazuaki Yokoyama, Lim Lay Ahyoung, Michiko Koga, Hiroyuki Sakamoto, Narikazu Boku, Dai Shida, and Hiroshi Yotsuyanagi
- Subjects
intestinal behçet disease ,myelodysplastic syndrome ,trisomy 8 ,parenteral nutrition ,case report ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Intestinal Behçet disease (BD), associated with myelodysplastic syndrome (MDS), is often refractory to treatment. An 80-year-old man with trisomy 8 MDS (refractory anemia) developed intermittent fever. Despite investigations to exclude infectious disease, autoimmune disease, and malignancy as the cause of the fever, the etiology could not be determined. A colonoscopy revealed several shallow round ulcers in the ileocecal region and ascending colon, and the biopsy specimens showed nonspecific inflammation. Thereafter, the patient experienced abdominal pain and diarrhea. Other than an oral aphthous ulcer, the patient did not show symptoms to meet the diagnostic criteria for BD. The patient was diagnosed with intestinal ulcers (intestinal BD-like disease) with MDS and trisomy 8. After treatment failure with 5-aminosalicylic acid, steroid, colchicine, and azacitidine, cerebral infarction occurred. Eating was difficult because of the patient’s impaired consciousness; hence, total parenteral nutrition (TPN) was commenced. The fever and abdominal symptoms improved with bowel rest over approximately 1 month. Small amounts of food were orally administered to the patient following recovery from the after-effects of the cerebral infarction, but diarrhea and fever repeatedly flared up. Therefore, TPN was continued at home. The patient has not experienced any further intestinal BD symptoms for approximately 1 year with bowel rest. Nutritional therapy, including bowel rest, may be an effective treatment option for intestinal BD with MDS, and might be used as an induction therapy of remission or a supportive therapy for other treatments.
- Published
- 2023
- Full Text
- View/download PDF
46. Use of TYK2 inhibitor to relieve reactive granulomatous dermatitis due to myelodysplastic syndrome
- Author
-
Christina Huang, BS, Adar Berghoff, MD, and Jack L. Arbiser, MD, PhD
- Subjects
Granuloma formation ,myelodysplastic syndrome ,TYK2 Inhibition ,Dermatology ,RL1-803 - Published
- 2023
- Full Text
- View/download PDF
47. Integrated medical and nursing ward rounds in a patient with myelodysplastic syndrome (医护一体化查房模式下1例骨髓增生异常综合征患者的护理体会)
- Author
-
MA Huigai (马会改), BAI Yu (白羽), and LIU Pingping (刘萍萍)
- Subjects
integration of medical care ,nursing ward rounds ,myelodysplastic syndrome ,traditional chinese medicine nursing ,医护一体化 ,护理查房 ,骨髓增生异常综合征 ,中医护理 ,Nursing ,RT1-120 - Abstract
To review the clinical data of a patient with myelodysplastic syndrome and summarize the experience of treatment and nursing under the integrated mode of medical care. In the integrated medical and nursing ward rounds, doctors carried out symptomatic diagnosis and treatment, and used bedside physical examination combined with Traditional Chinese medicine. Nurses gave care based on syndrome differentiation, intradermal acupuncture treatment and moxibustion treatment intervention, and improved psychological evaluation and health education. In addition, patients were encouraged to actively cooperate with treatment and care. The implementation of integrated ward rounds can effectively improve the adverse reactions of chemotherapy in patients with myelodysplastic syndrome, improve treatment compliance, promote rehabilitation, and enhance the quality of nursing services. The integrated medical and nursing ward rounds is beneficial for the enhancement of medical care cooperation, sense of participation among nursing workers, and is conducive to the improvement of nursing quality. (本文回顾1例骨髓增生异常综合征患者的临床资料, 总结医护一体化模式下的治疗和护理经验。医护一体化模式下, 医生开展对症诊疗, 采用床旁查体联合中药方剂治疗; 护士实施辨证施护, 给予皮内针治疗及艾条灸治疗干预, 并完善心理评估和健康教育。此外, 鼓励患者积极配合治疗和护理。实施医护一体化查房, 能有效缓解骨髓增生异常综合征患者化疗的不良反应, 提高治疗依从性, 促进康复, 提升护理服务质量。医护一体化查房加强了医护合作, 可提升护理工作者的参与感, 进而有利于护理质量的提升。)
- Published
- 2023
- Full Text
- View/download PDF
48. Identification of Plasma Thrombopoietin Level and Its Significance in Patients with Aplastic Anemia and Myelodysplastic Syndrome
- Author
-
Mengying Zhang, Gaochao Zhang, Fangfang Xu, Mengyuan Liu, Xifeng Dong, Weiwei Qi, and Huaquan Wang
- Subjects
aplastic anemia ,myelodysplastic syndrome ,thrombopoietin ,Genetics ,QH426-470 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Objective Our objective was to investigate the concentration of plasma thrombopoietin (TPO) in patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS), as well as its relationship with patients' responses to recombined human TPO (rhTPO) therapy.
- Published
- 2023
- Full Text
- View/download PDF
49. Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada
- Author
-
John Paul Yun, Philip Q. Ding, Aastha Dolley, and Winson Y. Cheung
- Subjects
myelodysplastic syndrome ,chronic myelomonocytic leukemia ,real-world evidence ,hypomethylating agents ,treatment patterns ,patient support programs ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
The management of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is limited and remains an unmet need. Decitabine/cedazuridine (DEC-C, ASTX727) is Canada’s first and only approved oral hypomethylating agent for MDS and CMML. We characterized the real-world use of DEC-C through a Canadian compassionate use program. Demographic and clinical data from 769 patients enrolled in Taiho Pharma Canada’s Patient Support Program were collected and analyzed. These patients represent a collection period from 10 November 2020 to 31 August 2022 with a median age of 76 years. Among 651 patients who started DEC-C, the median treatment duration was 4.2 cycles. The median overall and progression-free survival were 21.6 and 10.7 months, respectively. Among 427 patients who discontinued treatment, the majority (69.5%) stopped due to death (n = 164) or disease progression (n = 133). Multivariable cox regression showed that age, province of residence, blast counts, antibiotic prophylaxis, and number of dose reductions and delays were not significantly associated with overall and progression-free survival. DEC-C is a promising alternative to parenteral hypomethylating agent therapy, and it likely addresses an important unmet need for effective and convenient therapies in this setting.
- Published
- 2023
- Full Text
- View/download PDF
50. Booster effect of a third mRNA‐based COVID‐19 vaccine dose in patients with myeloid malignancies
- Author
-
Akio Mori, Masahiro Onozawa, Mirei Kobayashi, Shihori Tsukamoto, Hajime Senjo, Takashi Ishio, Emi Yokoyama, Minoru Kanaya, Koh Izumiyama, Makoto Saito, Haruna Muraki, Masanobu Morioka, Takanori Teshima, and Takeshi Kondo
- Subjects
acute myeloid leukemia ,booster vaccine effect ,COVID‐19 ,myelodysplastic syndrome ,SARS‐CoV‐2 ,vaccine ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background We have reported that seroconversion rates after the second dose of mRNA‐based COVID‐19 vaccines for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) were 100% and 95% respectively, with no significant difference from healthy controls (HCs).However, there are very limited data for the response to a third vaccine dose in those patients. Aims In this complementary study, we investigated the booster effect of a third mRNA‐based COVID‐19 vaccine dose in patients with myeloid malignancies. Materials & Methods A total 58 patients including 20 patients with MDS and 38 patients with AML were enrolled. Anti‐SARS‐CoV‐2S immunoassays were performed at 3, 6, and 9 months after the second vaccine dose. Results Seventy‐five percent of the MDS patients and 37% of the AML patients were receiving active treatment at the time of the third vaccination. Both the initial and third vaccine response in AML patients were comparable to those in HCs. In MDS patients, although the initial vaccine immunogenicity was inferior to that in HCs and AML patients, the third vaccine improved the response to a level not inferior to those in HCs and AML patients. Of note, the third vaccine resulted in a significant increase of antibodies in actively treated MDS patients who had shown a response inferior to that in untreated patients after two doses of vaccination. Discussion In patients with myeloid malignancies, the third vaccine dose showed a booster effect, and disease‐ and therapy‐related factors associated with the booster response have been identified. Conclusion The third dose of an mRNA‐based COVID‐19 vaccine showed a booster effect in patients with myeloid malignancies. Such a good booster response has not been reported in other haematological malignancies.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.